Compare Global Payments Inc (GPN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Neurocrine Biosciences Inc — how do they compare? Global Payments Inc trades at $82.46 (market cap $21.46B), while Neurocrine Biosciences Inc trades at $141.27 (market cap $14.36B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GPN | NBIX | |
|---|---|---|
Market Cap | $21.46B | $14.36B |
Volume | 1,482,600 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $94.83 | $185.50 |
52-Week Low | $62.47 | $123.10 |
Typical Hold Time | 50 Days | 23 Days |
Enterprise Value | $39.60B | $14.37B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $81.08, down 0.87% on the day, with a bearish technical signal and mixed fundamentals. The stock has beaten earnings estimates for the last three quarters, but 2026 projections show a net loss. Analyst consensus is bullish with a $102.75 price target, though rising debt and competition pose risks.
The outlook hinges on successful integration of Genius and Worldpay platforms to drive growth, but investor caution is warranted due to negative profit margins forecasted for 2026 and high debt levels. Near-term price action is testing key support at $80.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
